DARIFENACIN HYDROBROMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Darifenacin Hydrobromide, and what generic alternatives are available?
Darifenacin Hydrobromide is a drug marketed by Alembic, Aurobindo Pharma, Cipla, Endo Operations, Jubilant Generics, Polygen Pharms, Torrent, and Xiromed. and is included in eight NDAs.
The generic ingredient in DARIFENACIN HYDROBROMIDE is darifenacin hydrobromide. There are nineteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the darifenacin hydrobromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Darifenacin Hydrobromide
A generic version of DARIFENACIN HYDROBROMIDE was approved as darifenacin hydrobromide by CIPLA on September 1st, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DARIFENACIN HYDROBROMIDE?
- What are the global sales for DARIFENACIN HYDROBROMIDE?
- What is Average Wholesale Price for DARIFENACIN HYDROBROMIDE?
Summary for DARIFENACIN HYDROBROMIDE
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 8 |
| Finished Product Suppliers / Packagers: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 1 |
| Patent Applications: | 19 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DARIFENACIN HYDROBROMIDE |
| DailyMed Link: | DARIFENACIN HYDROBROMIDE at DailyMed |
Recent Clinical Trials for DARIFENACIN HYDROBROMIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Toronto Rehabilitation Institute | Phase 4 |
| Ontario Neurotrauma Foundation | Phase 4 |
Pharmacology for DARIFENACIN HYDROBROMIDE
| Drug Class | Cholinergic Muscarinic Antagonist |
| Mechanism of Action | Cholinergic Muscarinic Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for DARIFENACIN HYDROBROMIDE
Paragraph IV (Patent) Challenges for DARIFENACIN HYDROBROMIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ENABLEX | Extended-release Tablets | darifenacin hydrobromide | 7.5 mg and 15 mg | 021513 | 3 | 2008-12-22 |
US Patents and Regulatory Information for DARIFENACIN HYDROBROMIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic | DARIFENACIN HYDROBROMIDE | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 207681-001 | Dec 8, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Endo Operations | DARIFENACIN HYDROBROMIDE | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 091190-001 | Mar 13, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aurobindo Pharma | DARIFENACIN HYDROBROMIDE | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 206743-002 | Sep 19, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Polygen Pharms | DARIFENACIN HYDROBROMIDE | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 211045-002 | Jan 6, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for DARIFENACIN HYDROBROMIDE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| pharmaand GmbH | Emselex | darifenacin hydrobromide | EMEA/H/C/000554 Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome. |
Authorised | no | no | no | 2004-10-22 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
